Tags

Type your tag names separated by a space and hit enter

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Braz J Psychiatry 2012; 34 Suppl 1:S104-10BJ

Abstract

OBJECTIVES

To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.

METHOD

The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints.

RESULTS

Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.

CONCLUSION

Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.

Authors+Show Affiliations

Laboratory of Panic and Respiration, Institute of Psychiatry, Universidade Federal do Rio de Janeiro, Brazil. alexschier@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng por

PubMed ID

22729452

Citation

Schier, Alexandre Rafael de Mello, et al. "Cannabidiol, a Cannabis Sativa Constituent, as an Anxiolytic Drug." Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), vol. 34 Suppl 1, 2012, pp. S104-10.
Schier AR, Ribeiro NP, Silva AC, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Braz J Psychiatry. 2012;34 Suppl 1:S104-10.
Schier, A. R., Ribeiro, N. P., Silva, A. C., Hallak, J. E., Crippa, J. A., Nardi, A. E., & Zuardi, A. W. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), 34 Suppl 1, pp. S104-10.
Schier AR, et al. Cannabidiol, a Cannabis Sativa Constituent, as an Anxiolytic Drug. Braz J Psychiatry. 2012;34 Suppl 1:S104-10. PubMed PMID: 22729452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. AU - Schier,Alexandre Rafael de Mello, AU - Ribeiro,Natalia Pinho de Oliveira, AU - Silva,Adriana Cardoso de Oliveira e, AU - Hallak,Jaime Eduardo Cecílio, AU - Crippa,José Alexandre S, AU - Nardi,Antonio E, AU - Zuardi,Antonio Waldo, PY - 2011/03/02/received PY - 2011/12/18/accepted PY - 2012/6/26/entrez PY - 2012/6/29/pubmed PY - 2013/2/1/medline SP - S104 EP - 10 JF - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JO - Braz J Psychiatry VL - 34 Suppl 1 N2 - OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD: The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints. RESULTS: Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder. CONCLUSION: Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined. SN - 1809-452X UR - https://www.unboundmedicine.com/medline/citation/22729452/Cannabidiol_a_Cannabis_sativa_constituent_as_an_anxiolytic_drug_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1516-44462012000500008 DB - PRIME DP - Unbound Medicine ER -